US · Healthcare · Medical Devices
EPS came in at 0.70 against a street estimate of 0.61 — a beat of 14.8%.
Analysts rate DexCom Inc a strong buy (24 buy, 3 hold, 0 sell out of 27) with an average price target of $94.12.
CONFIDENT Dexcom beat on revenue (+13% YoY) and earnings, raised FY26 guidance. Type 2 non-insulin CONNECT trial delivered strong A1c data. G7 15-Day conversion tracking to 50% by year-end; gross margins expanding despite Ireland factory ramp. Q2 FY26 U.S. revenue $933M; OUS $375M with 16% organic growth. Strong in France, Canada post-coverage expansion. Dexcom Flex launched in Germany for type 2 basal/non-insulin. Analysts pressed sustainability of double-digit growth (9M uncovered eligible remains), physician awareness of coverage (sales force deploying claims data + CONNECT), and G7 15-Day margin timing (steady multiyear uplift, not single quarter peak). Management emphasized breadth of coverage wins, product satisfaction gains (NPS), and Ireland as temporary headwind before 2027 acceleration. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.33% |
| Vanguard Capital Management, LLC | 6.63% |
| Vanguard Portfolio Management, LLC | 5.09% |
| State Street Corp | 4.75% |
| Baillie Gifford & Co Limited. | 3.92% |
| Amvescap Plc. | 3.62% |
| AllianceBernstein L.P. | 3.42% |
| Geode Capital Management, LLC | 3.27% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 DEXCOM, INC. (DXCM) - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Jereme Sylvain promoted from EVP, Chief Financial Officer to EVP, Chief Opera | 2026-09-14 |
| Board / officer change · Q3 2026 DEXCOM, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Dexcom announced the appointment of Glenn S. Boehnlein as a new director, effective | 2026-09-10 |
| Quarterly report · Q2 2026 DEXCOM, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1,308.4 million (up 13.1% vs Q2 2025: $1,157.1 million) • H1 2026 Revenue: | 2026-07-30 |
| Results announced · Q3 2026 DEXCOM Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $1.308 billion, up 13% year-over-year (12% organic) • U.S. Revenue: $93 | 2026-07-30 |
| Shareholder vote results · Q2 2026 DEXCOM, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 27, 2026 • 385,872,977 total shares outstanding as of April 1, 2026 (reco | 2026-05-28 |
| Reg FD disclosure · Q2 2026 DEXCOM, INC. (DXCM) - FORM 8-K SUMMARY HEADLINE NUMBERS • 2030 Organic Revenue Growth Target: 10%+ annually through 2030 • 2030 Non-GAAP Gross Profi | 2026-05-15 |
| Quarterly report · Q1 2026 DEXCOM, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $1,191.9 million (up 15% from $1,036.0 million in Q1 2025) • Q1 2026 Net Inc | 2026-04-30 |
| Results announced · Q2 2026 DEXCOM Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Revenue: $1.192 billion, up 15% year-over-year reported basis; 12% organic growth • U.S. | 2026-04-30 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes $1.0 billion share repurchase program through June 2027 On May 14, 2026, Dexcom's Board of Directors approved a $1 billion share repurchase program, effective through June 30, 2027. This replaces the previous repurchase program, which had $250 mi | 2026-05-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for DexCom Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.